Advertisement
Advertisement
KRYS
Krystal Biotech, Inc. Common Stock
309.56
USDSponsored
-3.32
-1.06%
May 12, 13:39 UTC -4
Open
KRYS Earnings Reports
Positive Surprise Ratio
KRYS beat 20 of 35 last estimates.
57%
Next Report
Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$128.98M
/$1.80
Implied change from Q1 26 (Revenue/ EPS)
+10.84%
/-1.64%
Implied change from Q2 25 (Revenue/ EPS)
+34.29%
/+39.53%
Krystal Biotech, Inc. Common Stock earnings per share and revenue
On May 04, 2026, KRYS reported earnings of 1.83 USD per share (EPS) for Q1 26, beating the estimate of 1.44 USD, resulting in a 26.33% surprise. Revenue reached 116.36 million, compared to an expected 114.37 million, with a 1.73% difference. The market reacted with a +7.86% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of 1.80 USD, with revenue projected to reach 128.98 million USD, implying an decrease of -1.64% EPS, and increase of 10.84% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Halozyme Therapeutics, Inc.
Report Date
May 11, 2026 For Q1 26
Estimate
$1.56
Actual
$1.60
Surprise
+2.52%
Legend Biotech Corporation - ADR
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.02
Actual
-$0.15
Surprise
-597.67%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.53
Actual
-$0.52
Surprise
+3.60%
Arvinas, Inc
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.93
Actual
-$0.90
Surprise
+4.00%
Tenax Therapeutics, Inc.
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.40
Actual
-$0.35
Surprise
+14.22%
SAB Biotherapeutics, Inc. Common Stock
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.23
Actual
-$0.35
Surprise
-50.28%
Acumen Pharmaceuticals, Inc. Common Stock
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.41
Actual
-$0.33
Surprise
+19.67%
Imunon, Inc. Common Stock
Report Date
May 12, 2026 For Q1 26
Estimate
-$1.13
Actual
-$0.84
Surprise
+25.81%
Acurx Pharmaceuticals, Inc. Common Stock
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.64
Actual
-$0.62
Surprise
+4.28%
Quince Therapeutics, Inc. Common Stock
Report Date
May 11, 2026 For Q1 26
Estimate
-$2.61
Actual
-$0.59
Surprise
+77.41%
FAQ
What were Krystal Biotech, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Krystal Biotech, Inc. Common Stock reported EPS of $1.83, beating estimates by 26.33%, and revenue of $116.36M, 1.73% above expectations.
How did the market react to Krystal Biotech, Inc. Common Stock's Q1 2026 earnings?
The stock price moved up 7.86%, changed from $266.04 before the earnings release to $286.95 the day after.
When is Krystal Biotech, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 03, 2026.
What are the forecasts for Krystal Biotech, Inc. Common Stock's next earnings report?
Based on 6
analysts, Krystal Biotech, Inc. Common Stock is expected to report EPS of $1.80 and revenue of $128.98M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement